The ever-increasing number of clinical conferences, particularly in cardiology, can sometimes take on a mind-numbing sameness as attendees sit through the presentation of still another patient subset of a drug-eluting stent (DES). What distinguishes the annual Summer in Seattle meeting is the Emerging Technologies Symposium held as part of the conference, at which future areas of interest within cardiology are identified and early-stage companies active in that space are given the opportunity to make presentations. Mark Reisman, MD, of Seattle's Swedish Medical Center, and William A. Gray, MD, of Columbia University Medical Center , the conference directors, have been successful in highlighting the next and the next-next areas of interest in cardiovascular medicine and have been able to attract very early-stage companies to discuss those areas, no small feat when it comes to device start-ups.
What's Hot in Cardiology beyond DES? Try Structural Heart Disease
Structural heart disease was prominently featured during the Emerging Technologies Symposium held during this year's Summer in Seattle cardiovascular conference.
More from Innovation
After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.
Rising Leader Jacob Rubens, who has co-founded and led several Flagship companies and is now origination partner, believes aspiring leaders should follow their bliss.
As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.
Appointed CEO 12 months ago, Anthony Costello wasted no time in orchestrating strategic change at Medidata. He talked to In Vivo about the art of the pivot and how to constantly push boundaries.
More from In Vivo
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Good medical device regulation brings balance and builds bridges between healthcare stakeholders. It also accords equal priority to innovation and patient safety. A zero-risk policy cannot achieve these goals, says Christina Ziegenberg, BVMed’s head of regulatory affairs of six years.
During Q1, biopharmas brought in an aggregate $13.1bn in financing and device company fundraising totaled $5bn; while in vitro diagnostic firms and research tools players raised $418m.